TH — Target Hospitality Corp. Stock Price, Chart & AI Report

Positive Oct 13, 2026 • 12:55 UTC Zacks Investment Research • Zacks.Com

Wall Street Analysts Think Target Hospitality (TH) Could Surge 39.76%: Read This Before Placing a Bet

Target Hospitality (TH) stock has gained 1.6% over the past four weeks and closed at $18.84. Wall Street analysts have set a mean price target of $26.33, suggesting a potential 39.8% upside. The stock has a Zacks Rank #2 (Buy) rating, supported by strong earnings estimate revisions with a 18.4% increase over the last 30 days. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets.

TH Target Hospitality price target earnings estimate revisions Zacks Rank stock upside analyst consensus

Sentiment note

Strong analyst consensus with mean price target of $26.33 (39.8% upside from current $18.84), Zacks Rank #2 (Buy) rating, and significant positive earnings estimate revisions (18.4% increase over 30 days) indicate bullish sentiment. However, the article emphasizes caution regarding over-reliance on price targets.

Positive Oct 9, 2026 • 12:55 UTC Zacks Investment Research • Zacks.Com

Bears are Losing Control Over Target Hospitality (TH), Here's Why It's a 'Buy' Now

Target Hospitality (TH) stock has declined 10.5% over the past week but formed a hammer chart pattern suggesting potential trend reversal. The company has a Zacks Rank #2 (Buy) rating with consensus EPS estimates for the current year increased 18.3% over the last 30 days, indicating improving earnings prospects and analyst optimism.

TH Target Hospitality hammer chart pattern trend reversal earnings estimate revisions Zacks Rank technical analysis bullish indicator

Sentiment note

Despite recent 10.5% decline, the stock shows technical reversal signals (hammer pattern) combined with strong fundamental improvements: 18.3% increase in consensus EPS estimates over 30 days and Zacks Rank #2 (Buy) rating, indicating analyst confidence in improving earnings prospects and potential near-term price appreciation.

Positive Oct 5, 2026 • 15:45 UTC Zacks Investment Research • Na

Here is Why Growth Investors Should Buy Target Hospitality (TH) Now

Target Hospitality (TH) is highlighted as a compelling growth stock with a Zacks Growth Score of A and Zacks Rank #2 (Buy). The company demonstrates exceptional earnings growth of 87.3% expected this year, well above the industry average of 29.1%, along with strong sales growth of 35.4% and efficient asset utilization. Positive earnings estimate revisions, which have surged 47.3% over the past month, further support the bullish outlook for the stock.

TH growth stock earnings growth asset utilization earnings estimate revisions Zacks Rank hospitality sector

Sentiment note

The company demonstrates exceptional fundamentals including 87.3% projected EPS growth (vs. 29.1% industry average), 35.4% sales growth (vs. 3.9% industry average), above-average asset utilization ratio of 0.61 (vs. 0.5 industry average), and strong upward earnings estimate revisions of 47.3% over the past month. Combined with a Growth Score of A and Zacks Rank #2, these factors position the stock favorably for outperformance.

Neutral Apr 2, 2026 • 13:30 UTC Benzinga • Rishabh Mishra

Stock Market Today: S&P 500, Nasdaq Futures Plunge As Trump 'Re-Escalates' War With Iran— Micron Technology, IBM, General Motors In Focus (UPDATED)

U.S. stock futures declined sharply on Thursday as President Trump escalated military tensions with Iran, threatening strikes on Iranian infrastructure for another two to three weeks. The S&P 500, Dow, and Nasdaq 100 all fell in premarket trading, with crude oil rising 6.74% amid geopolitical uncertainty. Key stocks including Micron Technology, General Motors, and IBM experienced declines, while analyst sentiment remains cautiously optimistic on long-term U.S. economic growth despite near-term volatility.

MU GM IBM LMT geopolitical tension Iran escalation market volatility crude oil

Sentiment note

Stock declined 0.079% despite securing $550 million data center contract and raising FY26 sales guidance. Strong price trends across all timeframes suggest positive fundamentals despite minor decline.

Negative Aug 7, 2025 • 13:11 UTC The Motley Fool • Jesterai

Target Hospitality (TH) Q2 Revenue Up 9%

Target Hospitality reported Q2 2025 revenue of $61.6 million, beating analyst expectations, but experienced significant profitability challenges due to terminated government contracts. The company raised full-year guidance and is focusing on diversifying revenue streams through new long-term contracts.

TH workforce lodging hospitality services government contracts revenue diversification

Sentiment note

Despite beating revenue estimates, the company experienced a 38.8% revenue decline, 93.3% drop in Adjusted EBITDA, and significant losses from terminated government contracts. The negative impacts were partially offset by new contract wins and raised guidance.

Negative Aug 27, 2024 • 01:00 UTC GlobeNewswire Inc. • N/A

Bragar Eagel & Squire, P.C. Is Investigating Metagenomi, Target Hospitality, Helios, and LegalZoom and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential securities law violations and other unlawful business practices by Metagenomi, Target Hospitality, Helios, and LegalZoom.

MGX TH HLIO LZ Metagenomi Target Hospitality Helios LegalZoom

Sentiment note

Target Hospitality's stock price fell significantly after the company announced the termination of its services agreement with the U.S. government.

Unknown Jun 26, 2024 • 11:30 UTC GlobeNewswire Inc. • Theratechnologies

Theratechnologies annoncera ses résultats financiers du deuxième trimestre de l’exercice financier de 2024 et fera une mise à jour de ses activités

MONTRÉAL, 26 juin 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement et la commercialisation de traitements innovateurs, annonce aujourd’hui que la Société dévoilera ses résultats pour le deuxième trimestre de l’exercice financier de 2024, clos le 31 mai 2024, et fera le point sur ses activités, le mercredi 10 juillet 2024, à 8 h 30 (HE).

TH THTX Calendar of Events

Unknown Jun 26, 2024 • 11:30 UTC GlobeNewswire Inc. • Theratechnologies

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its second quarter ended May 31, 2024, on Wednesday, July 10 at 8:30 a.m. ET.

TH THTX Calendar of Events

Unknown Jun 4, 2024 • 13:15 UTC Zacks Investment Research • Zacks Equity Research

Royal Caribbean Cruises Ltd. (RCL) Hits Fresh High: Is There Still Room to Run?

Royal Caribbean (RCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

RCL TH

Unknown May 29, 2024 • 13:40 UTC Zacks Investment Research • Zacks Equity Research

Are Investors Undervaluing Target Hospitality (TH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

TH

Unknown May 23, 2024 • 21:00 UTC GlobeNewswire Inc. • Theratechnologies

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

MONTREAL, May 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced Phase 1 data demonstrating signs of long-term efficacy and a manageable safety profile of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in patients with solid tumors. The data will be presented in a poster session on June 1, 9:00 AM-12:00 PM CDT (abstract #3081, poster board #226) at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, which is taking place May 31-June 4, 2024, in Chicago, IL.

TH THTX Calendar of Events Health Trade Show

Unknown May 23, 2024 • 21:00 UTC GlobeNewswire Inc. • Theratechnologies

Theratechnologies fait une présentation sur le sudocétaxel zendusortide au Congrès 2024 de l’ASCO qui montre des signes d’une efficacité à long terme et un profil d’innocuité gérable chez les patients atteints de tumeurs solides

MONTRÉAL, 23 mai 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au point et la commercialisation de traitements novateurs, a annoncé aujourd’hui des données de phase I établissant des signes d’efficacité à long terme et un profil d’innocuité gérable de son principal conjugué peptide-médicament (CPM) expérimental, le sudocétaxel zendusortide (TH1902), dans le traitement de patients atteints de tumeurs solides. Les données seront présentées dans le cadre d’une séance d’affiches le 1er juin, de 9 h à 12 h (HAC) (résumé no 3081, panneau d’affichage no 226) au Congrès 2024 de l’ASCO (American Society of Clinical Oncology) qui aura lieu du 31 mai au 4 juin 2024, à Chicago (Illinois).

TH THTX Calendar of Events Health Trade Show